Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Rec
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 10.06 +0.85 (9.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.21 | 52 Week High | $2.43 | |||
| Open | $9.20 | 52 Week Low | $1.05 | |||
| Day High | $10.11 | P/E | N/A | |||
| Day Low | $9.14 | EPS | $-1.79 | |||
| Volume | 5,947,213 | |||||
